/Investor DB

Bering Capital

Venture capitalActively deploying

San Francisco · Seed–Growth · 9 people tracked

Find your way into Bering Capital

Sign up to see every warm intro you have to Bering Capital

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Bering Capital team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

✨ Fox Verdict
Sign up to see your fit

Investment thesis

Bering Capital emphasizes the primacy of great markets and great people aligned around a shared mission. The firm positions itself as a seasoned partner that supports companies through varied stages of growth, helping build fundamentally strong businesses by establishing early culture and trust. It stresses strategic insight applied early in a company's development, reliable expertise amid market volatility, and a forward-looking, visionary approach to building innovative businesses. Its publicized news centers on healthcare and oncology companies such as Coherus and CalciMedica, suggesting a strong orientation toward transforming healthcare and life sciences.

Source: firm website, verified Oct 25, 2026.

Stage
Seed–Growth
HQ
San Francisco, California, US
Instruments
Equity
Founded
2020
Tracked investments
15
Unicorns
2
IPOs
3

Team · 9 people

from the firm's website & curated & public directories
Evgeny Zaytsev· Managing Partner, MD, PhD

Managing Partner at Bering Capital, holding MD and PhD credentials.

Philip Sawyer· Managing Partnerin

Managing Partner at Bering Capital.

Graeme Currie· Venture Partner, PhD
Christopher Alafi· Advisor, DPhil

Advisor to Bering Capital, holding a DPhil.

George Painter· Advisor, PhD

Advisor to Bering Capital, holding a PhD.

Gregory B. Brown· Advisor, MD

Advisor to Bering Capital, holding an MD.

Stephen A. Sherwin· Advisor, MD

Advisor to Bering Capital, holding an MD.

Greg Brown· Advisorin

Gregory B. Brown, M.D. is CEO and a director of Memgen, Inc., a development-stage company working on next-generation viral immunotherapeutics including oncolytic viruses. He co-founded HCR Partners, a healthcare-focused asset management firm, and was previously a partner at Paul Capital Partners where he co-managed royalty investments; earlier he was co-head of investment banking and head of healthcare at Adams, Harkness & Hill and a biotechnology research analyst at Vector Securities International. Trained as a transplantation immunologist and thoracic and vascular surgeon, he holds a B.A. from Yale College, an M.D. from SUNY Upstate Medical Center, and an M.B.A. from Harvard Business School.

Evgeny Zatsev

What they invest in

from 6 of 15 portfolio companies

Biotech ×5Healthtech ×5Medical Devices ×2AI & Machine Learning ×1Digital Health ×1

HQs:United States×5

Investments · 15 tracked

founders shown can be your intro path
Atea Pharmaceuticalsateapharma.comNASDAQ: AVIR

Atea is a clinical-stage biopharmaceutical company developing oral direct-acting antiviral therapies for single-stranded RNA viruses, currently focused on a bemnifosbuvir and ruzasvir regimen in Phase 3 development for hepatitis C virus (HCV).

BiotechHealthtechBoston, US

Jean-Pierre Sommadossi, Ph.D.(Executive Officer, Director)Jean-Pierre Sommadossi(President, CEO and Chairman of the Board)inAndrea Corcoran(Chief Financial Officer, Executive Vice President, Legal, and Secretary)Janet Hammond(Chief Development Officer)inMaria Arantxa Horga(Chief Medical Officer)inJohn Vavricka(Chief Commercial Officer)in

Co-investorsATEM Capital FundBain Capital Life SciencesRA Capital

Calcimedicacalcimedica.comin𝕏NASDAQ: CALC

CalciMedica is a clinical-stage biopharmaceutical company developing CRAC (calcium release-activated calcium) channel inhibition therapies for serious acute and chronic inflammatory, immunologic, and cardiopulmonary diseases.

BiotechHealthtechLa Jolla, US

Kenneth A. Stauderman(Co-founder)inGonul Velicelebi(Co-founder)Daniel Geffken(Executive Officer)A. Rachel Leheny(Executive Officer, Director)Michael J. Dunn(Executive Officer)inStephen Bardin(Chief Financial Officer)in

Co-investorsAisling CapitalMESA VERDE VENTURE PARTNERSRevelation PartnersSanderling VenturesClarus VenturesOrbiMed

Coherus Biosciencescoherus.comin𝕏NASDAQ: CHRS

Coherus Oncology develops and commercializes immuno-oncology therapies, including the approved LOQTORZI, to treat patients with cancer.

BiotechHealthtechMedical DevicesRedwood City, US

Dennis M. Lanfear(Executive Officer, Director)Denny Lanfear(Founder)inAlan C. Herman(Executive Officer)inJean-Frederic Viret, Ph.D.(Executive Officer)Peter K. Watler, Ph.D.(Executive Officer)Barbara K Finck, M.D.(Executive Officer)

Co-investorsF-Prime CapitalHEALTHCARE ROYALTY PARTNERSSofinnova VenturesVenrock

Life Detection Technologieslifedetectiontechnologies.com

Life Detection Technologies (LDT) develops a machine-learning platform that monitors core vital signs such as overnight heart rate and respiratory rate to predict COPD exacerbations days before they occur.

AI & Machine LearningDigital HealthHealthtechMedical DevicesSunnyvale, US

Peter Rule(CEO)inEric Howie(Executive Officer, Director)Dave Vreeland(Director)Marc Thomas(Director)

BoardEarl Cohen(Board Member)

Co-investorsGoAhead VenturesInnova Memphis, Inc.

Neuvogenneuvogen.com

NEUVOGEN is a biotechnology company developing therapeutic cancer vaccines, using a whole tumor cell vaccine platform aimed at addressing the complexity of solid tumors.

BiotechHealthtech

OncoResponseoncoresponseinc.comMay 2023 · $14M

Clinical-stage immuno-oncology company developing antibodies derived from the immune systems of 'Elite' cancer responders.

BiotechHouston, US

Alice Bexon(Executive Officer)inClifford J. Stocks(Director, Executive Officer)inKamal D. Puri(Executive Officer)inChris Russell(Executive Officer)inRuss Hawkinson(Executive Officer)

BoardSteven Gillis(Director)in

Co-investors3B Future Health FundCanaan PartnersGreatPoint VenturesRiverVest Venture PartnersAlexandriaARCH Venture Partners+5 more

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

CellworksCoherus OncologyDragon VascularFocalThericsFusion MedicalInvuityLeap TherapeuticsOnco ResponsePrecision Pharmaceuticals Holdings

Exits · 3

3 IPOs

Atea PharmaceuticalsNASDAQ: AVIRCalcimedicaNASDAQ: CALCCoherus BiosciencesNASDAQ: CHRS

Portfolio news

latest coverage across their companies

Frequently asked questions

How many investments has Bering Capital made?
Bering Capital has 15 tracked investments, 3 of which have exited.
What stage does Bering Capital invest at?
Bering Capital invests at the Seed, Series A, Growth stages.
What sectors does Bering Capital focus on?
Bering Capital focuses on Biotech, Healthtech, Medical Devices.
Where is Bering Capital located?
Bering Capital is headquartered in San Francisco, US.
Who does Bering Capital co-invest with?
Bering Capital most often shares deals with F-Prime Capital, GoAhead Ventures, Sanderling Ventures, among 13 tracked co-investors.

Images

Bering Capital photo

Similar investors

Featured in lists